XGN News and Press, Exagen Inc. From 03/22/22

Exagen press release (NASDAQ:XGN): Q4 GAAP EPS of -$0.42 beats by $0.04. Revenue of $12.69M (+0.2% Y/Y) beats by $0.97M. For further details see: Exagen GAAP EPS of -$0.42 beats by $0.04, revenue of $12.69M beats by $0.97M

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE ® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022, AVISE test off...

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights: Record total revenue of $48.3 mil...

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with appointment of seven doctors and rheumatology experts. The SAB includes Stanle...

SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum, which takes place March 22-23, 2022. Ron Rocca, E...

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen’...

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022...

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus ...

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33 rd Annual Virtual Healthcare Conference. From November 22 nd to December 2 nd , present...

Exagen Inc. (XGN) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Paul Knig...